Department of Women's and Children's Health, Dunedin School of Medicine, Otago Medical School, University of Otago, Dunedin, New Zealand.
Department of Pediatrics, University of Otago, Christchurch, New Zealand.
Front Endocrinol (Lausanne). 2023 Aug 24;14:1214975. doi: 10.3389/fendo.2023.1214975. eCollection 2023.
To evaluate the experiences of patients with type 1 diabetes following transition from a calibration-requiring to a calibration-free sensor and remote monitoring in the context of using automated insulin delivery (AID).
Fifteen participants aged 7-65 years with type 1 diabetes participating in a longitudinal study used a Medtronic® advanced hybrid closed loop (AHCL) device with initially calibration-requiring then calibration-free sensors. Qualitative interviews were conducted ≥20 weeks following use of the calibration-requiring and ≥4 weeks after use of the calibration-free sensors/remote monitoring. Thematic analysis was used to identify key themes and subthemes.
At baseline, mean diabetes duration was 14.5 years ( ± 10.9), mean Hba1c 54.8 mmol/mol ( ± 10.2) (7.2 ± 0.9%) and Time in range 75.4% ( ± 11.6). Participants reported a progressive improvement in digital and lifestyle integration, and device trust following transition to calibration-free sensors with remote monitoring potential. They also reported a reduced need for capillary glucose, increased device satisfaction and trust, and reduced burden of diabetes care. Negative aspects reported included periodic early sensor loss, and for some, impaired integration with mobile devices.
Transitioning to calibration-free sensors with remote monitoring while using AHCL was associated with better user experience, including perceptions of improved quality of life and a reduced burden of diabetes care. Appropriate expectation setting, training, and ongoing support allow for the optimal user experience while using AHCL.
https://www.anzctr.org.au, identifier ACTRN12621000360819.
评估在使用自动胰岛素输送（AID）的情况下，1 型糖尿病患者从需要校准的传感器过渡到无需校准的传感器和远程监测后的体验。
15 名年龄在 7-65 岁之间的 1 型糖尿病患者参与了一项纵向研究，使用 Medtronic®先进混合闭环（AHCL）设备，最初使用需要校准的传感器，然后使用无需校准的传感器。在使用需要校准的传感器后≥20 周和使用无需校准的传感器/远程监测后≥4 周进行定性访谈。使用主题分析来确定关键主题和子主题。
基线时，平均糖尿病病程为 14.5 年（±10.9），平均 Hba1c 为 54.8mmol/mol（±10.2）（7.2±0.9%），时间在范围内为 75.4%（±11.6）。参与者报告说，在过渡到具有远程监测潜力的无需校准传感器后，数字和生活方式的整合以及对设备的信任度逐渐提高。他们还报告说，对毛细血管葡萄糖的需求减少，设备满意度和信任度提高，糖尿病护理负担减轻。报告的负面方面包括定期早期传感器丢失，以及对某些人来说，对移动设备的集成受到影响。
在使用 AHCL 时，过渡到无需校准的传感器和远程监测与更好的用户体验相关，包括感知到生活质量的提高和糖尿病护理负担的减轻。适当的期望设定、培训和持续支持允许在使用 AHCL 时获得最佳的用户体验。
https://www.anzctr.org.au，标识符 ACTRN12621000360819。
